Background: This pilot study evaluated the long-term outcomes of patients with
| INTRODUCTION
Laryngeal cancer is among the most common malignant tumors arising in the head and neck region. Although the overall incidence of squamous cell carcinoma of the larynx (SCC-L) has decreased over time, the associated survival rates have also decreased in past decades. 1 This change may be due to a shift from radical surgery to treatments such as radiotherapy (RT), chemoradiotherapy (CRT), and biotherapy, which aim to preserve the larynx and its functions. [2] [3] [4] Although total laryngectomy followed by radiotherapy is usually recommended for the treatment of locally advanced laryngeal cancer, this procedure often causes difficulties with breathing, speaking, and smelling, which reduce the quality of life. For these reasons, many institutions opt for intensive treatments, such as CRT, to improve organ and functional preservation, despite the lower survival rates of patients who receive with nonsurgical treatments. 5 The adverse effects of chemoradiation therapy, including laryngeal edema, mucosal fibrosis, and decreased laryngeal sensation, can lead to reduced respiratory and deglutitory functions. Generally, patients with T4 laryngeal cancer are treated via total laryngectomy according to the National Comprehensive Cancer Network (NCCN)
guidelines. 6 However, the management of advanced T2 or T3 laryngeal cancer has not been elucidated.
The selective radiotherapy and concomitant intra-arterial cisplatin (RADPLAT) regimen was first reported by Robbins et al in 1992 and has since been used to improve organ and functional preservation. 7 In Japan, reports have demonstrated favorable survival and organ preservation rates among patients with head and neck cancer who were treated with RADPLAT at several institutions. [8] [9] [10] [11] A Dutch randomized phase 3 trial that compared RADPLAT with intravenous (IV) cisplatin-based CRT did not identify any additional benefits of RADPLAT in terms of locoregional control (LRC) and survival. 12 However, that trial did not include patients with laryngeal cancer.
Although few studies have evaluated the use of RADPLAT in patients with SCC-L, 13, 14 very little is known about the long-term effects of this regimen on survival or the structural and functional preservation of the larynx. Accordingly, this retrospective study aimed to investigate survival outcomes, organ and functional preservation of the larynx, and toxicities in patients with advanced T2 or T3 SCC-L who underwent RADPLAT at a single institution. An intra-arterial cisplatin infusion was administered by the diagnostic radiologist and radiation oncologist using the Seldinger technique, which involves a transcutaneous femoral insert. A microcatheter was inserted intra-arterially and advanced selectively to the arteries that supplied nutrients to the tumors, including the superior thyroid artery and/or lingual artery. These nutrient-supplying arteries were identified using cone-beam CT and imaged using angiography (3D-CTA).
| MATERIALS AND METHODS

| Patients
Before the infusion of cisplatin, a 5-HTT3 receptor antagonist was administered intravenously to prevent nausea and vomiting. Cisplatin ) was administered intra-arterially at a flow rate of 0.1 mg s −1 . Simultaneously, sodium thiosulfate (20-25 g) was administered intravenously to neutralize the acidity of cisplatin and reduce the incidence of systemic toxicities such as renal dysfunction or vessel damage. The catheters were removed after drug administration, and saline was administered for 24 hours to protect renal function. Cisplatin was administered four times (total 300 mg), although an additional one or two cycles (75-150 mg) were given in cases with a suspected residual tumor.
| Radiotherapy
External radiotherapy was administered to all patients five times per week (1.8 Gy fraction
) using a three-dimensional (3D) method and 4-MV X-ray beam linear accelerator. In the primary region, the gross tumor volume (GTV) was evaluated using CT and/or MRI, and the clinical target volume (CTV) was defined as the GTV plus a safety margin of 5 mm. The planning target volume was calculated as the CTV F I G U R E 1 Schema of eligibility and response data to selective radiotherapy and concomitant intra-arterial cisplatin (RADPLAT). CDDP, cisplatin; CR, complete response; PD, progressive disease 
| Statistical analysis
LRC, disease-specific survival (DSS), and overall survival (OS) were calculated from the date of diagnosis using the Kaplan-Meier method.
Total laryngectomy, tracheostomy, and/or feeding tube placement/ retention after 2 years of treatment were defined as events associated with laryngeal preservation (LP) and function. 15 Freedom from laryngectomy (FFL) was defined according to the date of salvage laryngectomy for an event, while laryngectomy-free survival (LFS) was defined according to the date of salvage laryngectomy and/or any death related to an events. The functional and mortality endpoints were evaluated using the laryngo-esophageal dysfunction-free survival (LEDFS), which included death, local recurrence, salvage total laryngectomy, tracheotomy, and/or feeding tube placement/retention recorded after 2 years of treatment. The survival rates were compared using a log-rank test. Clinical variables associated with a P value <.2 in the univariate analysis were subjected to a multivariate analysis using the Cox proportional hazard model. Probabilities <.05 were considered statistically significant. All statistical analyses were conducted using JMP Pro 13 statistical software (SAS Institute, Cary, North Carolina).
3 | RESULTS
| Patient characteristics
Between Table 1 .
| Treatment outcomes
The total cisplatin dose range administered in this study was 150 to 450 mg, and the total irradiation dosage range was 60 to 71 Gy. At a total administered cisplatin dose of 150 mg and irradiation dose of 18 to 27 Gy, two of four patients had an early complete response (CR) to treatment at the local site as determined endoscopically, one had grade 3 dysphagia, and the fourth patient had a severe cough stimulated by inserting the catheter into the tumor feeding artery. In these patients, further cisplatin administration was stopped and radiotherapy alone was administered, although one patient also temporarily stopped receiving radiotherapy. At a total administered cisplatin dose of 225 mg and irradiation dose of 36 to 45 Gy, two of three patients achieved an early CR, and the third developed progressive disease.
Further cisplatin administration was stopped in the first two patients, who were given sequential radiotherapy, while the third patient oral cancer, n = 1; esophageal cancer, n = 1), while deaths due to locoregional recurrences and distant metastases occurred in two and three patients, respectively. (Figure 4 ).
| LRC and survival
| Prognostic factors
The results of the univariate analyses of LRC, DSS, and OS are shown in Table 2 . No significant differences were observed in terms of the LRC. In contrast, statistically significant associations were observed between the DSS and the N classification (P = .021), clinical stage (P = .017), and total cisplatin dosage (P = .010). classification (Table S1 ). The multivariate analyses identified the N classification as an independent and significant factor affecting DSS (hazard ratio [HR] = 6.64; 95% confidence interval [CI] = 1.07-51.69, P = .042).
The univariate analysis also indicated significant associations of the OS with the N classification (P = .020) and total cisplatin dosage (P = .037), while the multivariate analysis identified positive nodal disease as an independent and significant risk factor for OS (HR = 4.88; 95% CI = 1.42-15.49, P = .014).
| Toxicities
Grade 3 and 4 hematologic and nonhematologic toxicities were observed in nine (18%) and three (6%) patients, respectively (Table 3 ).
The following grade >3 toxicity events were observed: leukopenia in six (12%) patients, neutropenia in seven (8%), anemia in two (4%), thrombocytopenia in two (4%), dysphagia in one (2%), and pharyngeal mucositis in two (4%) patients. Although one patient temporarily stopped receiving sequential irradiation because of grade 3 dysphagia, the patient eventually completed the planned irradiation dosage (total dose: 61 Gy). Late toxicities were observed in two patients. One patient developed chondronecrosis of the cricoid cartilage and underwent debridement of the affected lesion, which preserved the larynx.
The other patient developed severe dysphasia 2 years after completing RADPLAT and underwent a laryngectomy.
| DISCUSSION
Most previous studies reported that organ-preserving therapies, including radiation therapy, chemoradiation therapy, and transoral laser microsurgery, are generally administered to patients with local early-stage laryngeal cancers. [16] [17] [18] In contrast, many patients with locally advanced tumors require radical surgery, including total or partial laryngectomy. [19] [20] [21] In this study, the 5-year LRC rates of patients with advanced T2 and T3 cancers were 90% and 81.6%, respectively, whereas the corresponding 5-year DSS rates and OS rates were 87.5% and 88.6%, respectively, and 87.5% and 81.5%, respectively.
Furthermore, for clinical stage II, III, and IVA disease, the 5-year LRC rates were 100%, 81.7%, and 71.4%, respectively, the 5-year DSS rates were 100%, 93.3%, and 53.6%, respectively, and the OS rates were 100%, 84.8%, and 53.6%, respectively. Table 4 summarizes a literature review of the different therapeutic options. In several studies of surgical treatments, including total laryngectomy, the 5-year OS rates ranged from 41% to 85.5%. 20, [22] [23] [24] [25] Although it is difficult to compare these earlier results directly with our findings, the survival rates in our study tended to be favorable. Specifically, the nonsurgical treatments, including definitive RT and systemic CRT, yielded 5-year local control (LC) or LRC rates of 62% to 65% and OS rates of 40 to 67% in patients with clinically advanced-stage disease. with IV-CRT, respectively, thereby demonstrating that CRT is a more favorable treatment for patients with T2b relative to RT alone. 30 In a recent study of LP, Timme et al calculated a 2-year LEDFS rate of 40% in patients with T3 disease treated with IV-CRT. 24 Fuller et al or genitourinary effects were also reported. 35 A Dutch randomized trial reported grade >2 hematological (52%), mucosal (50%), and renal (1%) toxicities in patients treated with intra-arterial CRT, although grade >2 renal toxicity was significantly less frequent in patients receiving intraarterial CRT, compared to intravenous CRT. 12 In our study, we observed no renal toxicity, although grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia occurred in 12%, 14%, 4%, and 4% of the cases, respectively. The frequencies of these adverse reactions were much lower than those reported previously in patients who received IV-CRT.
Although the intra-arterial approach via the Seldinger method has been reported to cause cerebrovascular accidents in some cases, 12,31 these did not occur in our study. Lin et al reported comparable survival outcomes in patients treated with surgery vs those who received complete CRT but not incomplete CRT. 36 In other words, their study emphasized the importance of completing the full course of CRT.
In our study, only one patient temporarily discontinued treat- 36 The Radiation Therapy Oncology Group Trial 9615 reported grade 3-5 hematologic and nonhematologic toxicity rates of 51% and 82%, respectively, 31 whereas the corresponding rates in our study were 18% and 6%, respectively. The toxicity rates in our study were also much lower than those reported from the original RADPLAT studies by Robbins et al. 31, 37 The lower toxicity rate in our study may be due to the lower dosage of intra-arterial cisplatin (75 mg body −1 wk −1 × 2-6 cycles; total median dosage, 300 mg body
) than that used in previous reports. 31, 37 Lambert et al reported that 23% of patients treated with IV-CRT developed late toxicities, including percutaneous endoscopic gastrostomy (7%), persistent dysphagia (6%), pharyngoesophageal stenosis (2%), and permanent tracheostomy (8.5%). 38 In our study, late toxicities such as chondronecrosis and severe dysphagia occurred in two patients (3.8%) within 5 years after RADPLAT, while no incident of late dysphagia occurred more than 5 years after RADPLAT. A long-term follow-up study of the RTOG 91-11 trial reported a higher rate of death due to reasons other than laryngeal cancer in the CRT group, suggesting that a higher cisplatin dose affects OS by inducing a high incidence of adverse events in the CRT group. 39 Although Furusaka et al reported higher rates of LP and survival in patients treated with three-agent chemotherapy (IA cisplatin and docetaxel combined with IV 5-fluorouracil), they also reported much higher grade 3-4 leukopenia, neutropenia, and mucositis rates than those in observed in our study. The lower-dose of cisplatin as a single agent and the lower frequencies of adverse events of our study may be due to the attempted long-term preservation during treatment for advanced laryngeal cancer. Therefore, new strategies that would improve organ preservation and function while reducing morbidity are needed.
The present study had several limitations. First, it was a retrospective study with a small cohort. Second, all treatments were performed at a single institution. Third, eligible patients in this study Abbreviations: CDDP, cisplatin; CHEP, cricohyoidoepiglottopexy; CRT, chemoradiation therapy; CSS, cancer-specific survival; DFS, disease-free survival; DOC, docetaxel; DSS, disease-specific survival; FFL, freedom from laryngectomy; ICT, induction chemotherapy; LC, local control; LEDFS, laryngoesophageal dysfunction-free survival; LFS, laryngectomy-free survival; LP, larynx preservation; LRC, locoregional control; OS, overall survival; PFS, progression-free survival; RADPLAT, radiotherapy and concomitant intra-arterial cisplatin; RFS, relapse-free survival; RT, radiation therapy.
were selected carefully, and the sample included few patients with nodal disease and an advanced clinical stage. Fourth, the frequency and total dose of cisplatin administration were not consistent. Further large-cohort analyses are required to validate these findings.
In conclusion, our study demonstrates that RADPLAT therapy is safe and feasible in patients with laryngeal cancer while enabling organ and functional preservation. However, the treatment protocol should be standardized. Additionally, the feasibility of RADPLAT therapy in patients with nodal disease and advanced clinical stage should be validated further, as only a few such patients were included in our study.
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